Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupAcute LeukemiasAggressive LymphomasIndolent LymphomasDiseaseAcute Lymphoblastic LeukaemiaChronic Lymphocytic Leukemia / Small Lymphocytic LymphomaMantle Cell LymphomaNHL, B-Cell Type, Burkitt's LymphomaNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular Grade I-IIIaNHL, B-Cell Type, Follicular grade IIIbNHL, B-Cell Type, IndolentSubgroupICD10C82.-C82.7C82.9C83.1C83.3C83.7C91.0-C91.1-MeSHLymphoma, Mantle-CellPrecursor B-Cell Lymphoblastic Leukemia-LymphomaSequenceIXAZ4/RITU1400/DEXA20, Waldenström (PID2025) -|- (PID2026) -|- (PID2027) -|- (PID310)ChemotherapyChemo-substanceAsparaginaseDexamethasoneEtoposideIfosfamideMethotrexateRituximabChemo-substanceAsparaginaseDexamethasoneEtoposideIfosfamideMethotrexateRituximabChemo-substanceAsparaginaseDexamethasoneEtoposideIfosfamideMethotrexateRituximabChemo-substanceAsparaginaseDexamethasoneEtoposideIfosfamideMethotrexateRituximabNo. Substances15 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDextrose 5%DimetindenFilgrastimFolinic acidFurosemideGranisetronMesnaNaCl 0.9%ParacetamolPotassium chloridePrednisoloneSodium BicarbonateSupportive substanceBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDextrose 5%DimetindenFilgrastimFolinic acidFurosemideGranisetronMesnaNaCl 0.9%ParacetamolPotassium chloridePrednisoloneSodium BicarbonateSupportive substanceBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDextrose 5%DimetindenFilgrastimFolinic acidFurosemideGranisetronMesnaNaCl 0.9%ParacetamolPotassium chloridePrednisoloneSodium BicarbonateSupportive substanceBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDextrose 5%DimetindenFilgrastimFolinic acidFurosemideGranisetronMesnaNaCl 0.9%ParacetamolPotassium chloridePrednisoloneSodium BicarbonateNo. Substances312Protocol classificationTherapy classificationcurrent standardIntensityhigh doseStandard doseTherapy indicationFirst lineTherapy phaseTherapy intentioncurativeRisksAnemia Hb below 8g/dlDiarrheaEmetogenicity (MASCC/ESMO)HyperbilirubinemiaHyperglycemiaHypoalbuminemiaHyponatremiaIncrease AminotransferasesInfectionsLeukopeniaMucositisNeutropeniaThrombocytopenia below 50 000/µl only studiesPublicationAuthorDavies AYamaguchi MDiseaseExtranodales NK/T-Zell Lymphom, Stadium III-IV, ErstlinieOriginCancer Research UK Centre, University of Southampton, UK, SABRINA StudieMie University Graduate School of Medicine, Tsu, JapanProtocols in Revision 2 protocols foundProtocols under revision.Rituximab 1400, single dose subcutaneous (PID310 V2.0)SMILE (Methotrexate 2000 / Ifosfamide 1.5 / Dexamethasone 40 / Etoposide 100 / Asparaginase 6000), extranodal NK/T-cell Lymphoma (PID2351 V1.0)
